ASTRAZENECA : UBS remains Neutral | MarketScreener
In a research note, UBS analyst Michael Leuchten has maintained his recommendation on the stock with a Neutral rating. The target price remains set at GBX 12500. | June 5, 2023
Stay updated with breaking news from Aintained. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
In a research note, UBS analyst Michael Leuchten has maintained his recommendation on the stock with a Neutral rating. The target price remains set at GBX 12500. | June 5, 2023
In a research note, UBS analyst Patrick Hummel has maintained his recommendation on the stock with a Buy rating. The target price remains set at EUR 17.5. | June 5, 2023
In a research note, UBS analyst Sam Arie has maintained his recommendation on the stock with a Neutral rating. The target price remains set at GBX 1135. | June 5, 2023
In a research note, Deutsche Bank analyst Adam Cochrane has maintained his recommendation on the stock with a Buy rating. The target price remains set at SEK 160. | June 2, 2023
In a research note, JP Morgan analyst Samik Chatterjee has maintained his recommendation on the stock with a Buy rating. The target price continues to be set at USD 190. | June 2, 2023